Asciminib is indicated for:
Irrespective of gender only Adults (18 years old or older)
Asciminib is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors.
For this indication, the medical literature mentions below treatments (click for details):
Active ingredient Asciminib is contraindicated in the following cases:
It is unknown whether asciminib/metabolites are excreted in human milk. There are no data on the effects of asciminib on the breast-fed newborn/infant or on milk production. Because of the potential for serious adverse reactions in the breast-fed newborn/infant, breast-feeding should be discontinued during treatment and for at least 3 days after stopping treatment with asciminib.